Jensen et al. JPGN 2016; 62: 36-42. The researchers used a large database (>75 million individuals) representative of US commercially-insured population to provide estimates of the prevalence of several eosinophilic disorders:
- Eosinophilic gastritis 6.3 per 100,000
- Eosinophilic gastroenteritis 8.4 per 100,000
- Eosinophilic colitis 3.3 per 100,000
In the associated commentary by Furuta et al (pg 1), clinicians are encouraged to urge patients with EGID to register on the Consortium for Eosinophilic Gastrointestinal Disease Research registry: https://www.rarediseasesnetwork.org/cms/CEGIR
Related blog posts:
- Anti-TNF Therapy for Eosinophilic Gastroenteritis
- Eosinophiliic Esophagitis NEJM Review -post also includes information on eosinophilic gastritis
Pingback: New Treatment for Eosinophilic Gastritis and Duodenitis | gutsandgrowth